Related Experiment Video
Updated: Apr 11, 2026

Describing a Transcription Factor Dependent Regulation of the MicroRNA Transcriptome
Published on: June 15, 2016
Microenvironmental interleukin-6 suppresses toll-like receptor signaling in human leukemia cells through miR-17/19A
Yanmei Li1, Yonghong Shi1, Lindsay McCaw1
1Biology Platform, Sunnybrook Research Institute, Toronto, Canada;
Abstract:
The regulation of toll-like receptor (TLR) signaling in a tumor microenvironment is poorly understood despite its importance in cancer biology. To address this problem, TLR7-responses of chronic lymphocytic leukemia (CLL) cells were studied in the presence and absence of a human stromal cell-line derived from a leukemic spleen. CLL cells alone produced high levels of tumor necrosis factor (TNF)-α and proliferated in response to TLR7-agonists. A signal transducer and activator of transcription 3 -activating stromal factor, identified as interleukin (IL)-6, was found to upregulate microRNA (miR)-17 and miR-19a, target TLR7 and TNFA messenger RNA, and induce a state of tolerance to TLR7-agonists in CLL cells. Overexpression of the miR-17-92 cluster tolerized CLL cells directly and miR-17 and miR-19a antagomiRs restored TLR7-signaling. Inhibition of IL-6 signaling with antibodies or small-molecule Janus kinase inhibitors reversed tolerization and increased TLR7-stimulated CLL cell numbers in vitro and in NOD-SCIDγc (null) mice. These results suggest IL-6 can act as tumor suppressor in CLL by inhibiting TLR-signaling.
Insights
Interleukin-6 (IL-6) can suppress chronic lymphocytic leukemia (CLL) growth by inhibiting toll-like receptor (TLR) signaling. This involves microRNAs targeting TLR7 and TNF-α, creating a tolerance that IL-6 blockade can reverse.
Area of Science:
- Immunology
- Cancer Biology
- Molecular Biology
Background:
- Toll-like receptor (TLR) signaling in the tumor microenvironment is crucial for cancer biology but poorly understood.
- Chronic lymphocytic leukemia (CLL) cells exhibit specific responses to TLR agonists.
Purpose of the Study:
- To investigate the regulation of TLR7 signaling in CLL cells within a tumor microenvironment.
- To identify factors contributing to TLR7 agonist tolerance in CLL.
Main Methods:
- Studied TLR7 responses of CLL cells with and without a human leukemic spleen stromal cell line.
- Analyzed the role of interleukin-6 (IL-6) and microRNAs (miR-17, miR-19a) in regulating TLR7 signaling.
- Utilized antagomiRs, IL-6 inhibition (antibodies, JAK inhibitors), and in vitro/in vivo models (NOD-SCIDγc mice).
Main Results:
- CLL cells produced high levels of tumor necrosis factor (TNF)-α and proliferated upon TLR7-agonist stimulation.
- IL-6 upregulated miR-17 and miR-19a, targeting TLR7 and TNF-α mRNA, inducing tolerance to TLR7 agonists.
- Inhibition of IL-6 signaling reversed tolerance, increasing TLR7-stimulated CLL cell proliferation in vitro and in vivo.
Conclusions:
- IL-6, via miR-17/19a, induces tolerance to TLR7 agonists in CLL cells.
- IL-6 signaling inhibition restores TLR7-mediated anti-leukemic responses.
- IL-6 may function as a tumor suppressor in CLL by inhibiting TLR signaling.
Related Concept Videos
T Cell Types and Functions
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
MicroRNAs
MicroRNAs

